nucleosome assembly protein 1 like 4 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored NAP1L4P3 profile across patient tissues and cancer cell-line models. NAP1L4P3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NAP1L4P3 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, NAP1L4P3 RNA expression shows 11,606 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where NAP1L4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAP1L4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAP1L4P3 survival associations across molecular data types. NAP1L4P3 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAP1L4P3 RNA expression–survival associations across cancer types. High NAP1L4P3 expression shows unfavorable associations in ACC and LIHC, but favorable associations in COAD, BLCA, MESO and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NAP1L4P3 RNA expression.
This table summarizes NAP1L4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for NAP1L4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAP1L4P3 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, READ, LUSC and KIRP. The COAD box plot shows higher NAP1L4P3 RNA expression in tumor versus normal tissue (log2 FC = +0.380, t-test p < 0.001).
This table shows molecular features associated with NAP1L4P3 in patient tissues and cancer cell lines. In patient samples, NAP1L4P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
